Contract research organizations (CROs), companies that provide research and clinical services to pharma and biotech clients, are finding success in an otherwise stagnant pharmatech dealmaking landscape. Despite relatively flat dealmaking overall in Q2 2024, CROs received $953.2 million across 35 deals driven by advancements in needs for next-generation therapeutics development and adoption of AI and precision medicine in clinical trials, according to PitchBook’s latest Emerging Tech Research report.
Read the full article: Research & Clinical-Focused Service Deals Continue to Grow in Pharmatech //
Source: https://pitchbook.com/news/reports/q2-2024-pharmatech-report